$56.37
Value $5.0B
LQDA and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$56.37
Value $5.0B
$691.33
Value $257B
Liquidia (LQDA) has a market value of $5.0B and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, LQDA moved +101.0% and TMO +19.9%. Dividend yield: LQDA none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LQDA$5.0B
TMO$257B
TMO is 52 times LQDA
Revenue, 12 months
LQDA$622M
TMO$47.4B
TMO is 76 times LQDA
Net income, 12 months
LQDA-$94M
TMO$7.1B
Operating margin
LQDA-15.6%
TMO17.9%
33.4 points apart
ROIC
LQDA-110.7%
TMO8.2%
118.9 points apart
P/E
LQDA–
TMO36.3
Dividend yield
LQDA0.0%
TMO0.3%
0.3 points apart
5-year return
LQDA+1,059.9%
TMO+10.9%
1,049.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LQDA+1,060.0%
TMO+10.9%
| Period | LQDAWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +101.0%Price +101.0% | +19.9%Price +19.5% |
| 3 years since November 16, 2023 | +793.3%+107.5% a yearPrice +793.3% | +47.7%+13.9% a yearPrice +46.3% |
| 5 years since November 15, 2021 | +1,059.9%+63.3% a yearPrice +1,059.9% | +10.9%+2.1% a yearPrice +9.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LQDALiquidiaTMOThermo Fisher Scientific
| Price | $56.37 | $691.33 |
|---|---|---|
| Market value | $5.0B | $257B |
| Enterprise value (EV) | – | $292B |
| P/E | – | 36.3 |
| P/E, 5-year median | – | 32.7 |
| P/B | – | 4.7 |
| EV/EBIT | – | 34.5 |
| Free cash flow yield | 5.9% | 3.0% |
| Revenue, 12 months | $622M | $47.4B |
|---|---|---|
| Net income, 12 months | -$94M | $7.1B |
| Free cash flow, 12 months | $291M | $7.6B |
| Earnings per share, 12 months | -$1.21 | $18.96 |
| Revenue growth, year on year | 1,031.2% | 3.9% |
| Revenue growth a year, past | +192.5%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | – | – |
|---|---|---|
| Operating margin | -15.6% | 17.9% |
| Net margin | -15.2% | 14.9% |
| ROIC | -110.7% | 8.2% |
| ROE | -136.5% | 13.4% |
| Cash | $396M | $6.1B |
|---|---|---|
| Total debt | – | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | -3.6× | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.4% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($257B) is about 51.7 times Liquidia ($5.0B), at today's prices.
Since November 15, 2021, LQDA's price moved +1,059.9% and TMO's +9.3%. With dividends: LQDA +1,059.9% (+63.3% a year), TMO +10.9% (+2.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Liquidia and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
Over the last twelve months, the net margin was -15.2% for Liquidia and 14.9% for Thermo Fisher Scientific, and the operating margin -15.6% and 17.9%. Revenue was $622M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.